Accustem Sciences Inc. (ACUT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Accustem Sciences Inc. (ACUT) trades at $0.225 with AI Score 42/100 (Grade C). Accustem Sciences Inc. is a life sciences company focused on improving cancer patient outcomes through its StemPrintER technology, a multi-gene prognostic assay. Market cap: $3.62M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ACUT: ACUT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACUT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACUT: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Accustem Sciences Inc. (ACUT) Healthcare & Pipeline Overview
Accustem Sciences Inc. is a biotechnology company specializing in prognostic assays for breast cancer recurrence, primarily through its StemPrintER technology. Operating with a small team, Accustem aims to provide personalized medicine solutions in the competitive healthcare sector, focusing on endocrine receptor-positive/HER2- breast cancer.
What Is the Investment Thesis for ACUT?
Accustem Sciences Inc. presents a focused investment opportunity within the biotechnology sector, centered on its StemPrintER technology for breast cancer recurrence prediction. The company's value drivers include the potential adoption of StemPrintER as a standard prognostic tool and the expansion of its application to other cancer types. Key growth catalysts include positive clinical trial results demonstrating the efficacy of StemPrintER and strategic partnerships with healthcare providers. The company's small market capitalization of $3.62M reflects both its growth potential and the risks associated with its early-stage development. Investors should monitor the company's progress in securing regulatory approvals and commercializing its products. The high beta of 2.44 indicates significant volatility, reflecting the speculative nature of biotechnology investments.
Based on FMP financials and quantitative analysis
ACUT Key Highlights
Market capitalization of $3.62M, indicating a small-cap company with potential for high growth but also higher risk.
- P/E ratio of -1.30, reflecting the company's current lack of profitability, common for early-stage biotechnology firms.
- Beta of 2.44, suggesting high volatility relative to the market, typical for companies in the biotechnology sector.
- Development of StemPrintER technology, a multi-gene prognostic assay for predicting breast cancer recurrence.
- Focus on personalized medicine and diagnostic tools to improve cancer treatment outcomes.
Who Are ACUT's Competitors?
ACUT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.56 | -12.80% | $38.4M | 45 |
| GTHP Guided Therapeutics, Inc. | $0.27 | +24.68% | $26.1M | 44 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACUT's Key Strengths?
Proprietary StemPrintER technology.
- Focus on personalized medicine.
- Potential for improved cancer treatment outcomes.
- Addresses a significant unmet need in breast cancer prognosis.
What Are ACUT's Weaknesses?
Small company with limited resources.
- Dependence on a single technology (StemPrintER).
- Lack of profitability.
- OTC market listing.
What Could Drive ACUT Stock Higher?
Clinical trials demonstrating the efficacy of StemPrintER.
- Potential regulatory approvals from agencies such as the FDA.
- Strategic partnerships with healthcare providers.
- Expansion of StemPrintER applications to other cancer types.
What Are the Key Risks for ACUT?
Financial-distress signal — its Altman Z-Score of -16.30 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established diagnostic companies.
- Technological obsolescence.
- Regulatory hurdles.
- Limited financial resources.
- Dependence on a single technology (StemPrintER).
What Are the Growth Opportunities for ACUT?
- Expansion of StemPrintER Applications: Accustem can expand the application of StemPrintER beyond Endocrine receptor-positive/HER2- breast cancer to other subtypes and potentially other cancer types. This would significantly increase the addressable market and revenue potential. The market for personalized cancer diagnostics is projected to reach $20 billion by 2028, offering a substantial opportunity for Accustem to capture market share through expanded applications of its core technology. Timeline: 2-3 years for initial expansion studies.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, cancer centers, and oncology practices can accelerate the adoption of StemPrintER and drive revenue growth. These partnerships would provide access to a broader patient base and facilitate the integration of StemPrintER into clinical workflows. The market for cancer diagnostics is highly fragmented, and strategic partnerships are crucial for gaining a competitive edge. Timeline: Ongoing.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA can enhance the credibility and market acceptance of StemPrintER. Regulatory approval would validate the clinical utility of the technology and facilitate reimbursement from insurance providers. The regulatory pathway for diagnostic assays can be complex and time-consuming, but successful approval can significantly increase the value of Accustem's technology. Timeline: 3-5 years.
- Development of Companion Diagnostics: Accustem can develop companion diagnostics that identify patients who are most likely to benefit from specific cancer therapies. This would align the company with the growing trend of personalized medicine and create opportunities for collaboration with pharmaceutical companies. The market for companion diagnostics is projected to reach $8 billion by 2027, driven by the increasing use of targeted therapies. Timeline: 2-4 years.
- International Expansion: Expanding into international markets, particularly Europe and Asia, can significantly increase Accustem's revenue potential. These markets offer large patient populations and growing demand for advanced cancer diagnostics. International expansion would require navigating different regulatory environments and establishing local partnerships, but the potential rewards are substantial. Timeline: 3-5 years.
What Are ACUT's Competitive Advantages?
- Proprietary StemPrintER technology.
- Multi-gene prognostic assay for breast cancer recurrence.
- Focus on personalized medicine and diagnostic tools.
- Potential for regulatory approvals and reimbursement.
What Does ACUT Do?
Accustem Sciences Inc., based in New York City, is a life sciences company dedicated to enhancing outcomes for cancer patients. The company's core technology is StemPrintER, a multi-gene prognostic assay designed to predict the risk of recurrence in patients with Endocrine receptor-positive/HER2- breast cancer. StemPrintER analyzes multiple genes to provide a more accurate prognosis, enabling physicians to tailor treatment plans for individual patients. Accustem also developed Spare, a derivative of StemPrintER that incorporates two clinical markers to further refine the prediction of recurrence risk. The company operates within the biotechnology industry, focusing on personalized medicine and diagnostic tools. Accustem's products aim to improve the precision of cancer treatment by providing clinicians with detailed prognostic information. The company's geographic focus is primarily within the United States, where it seeks to establish StemPrintER as a standard of care for breast cancer prognosis. Accustem competes with other diagnostic companies in the biotechnology sector, striving to differentiate itself through the accuracy and clinical utility of its StemPrintER technology.
What Products and Services Does ACUT Offer?
- Develop StemPrintER technology, a multi-gene prognostic assay.
- Predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer.
- Offer Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers.
- Focus on improving outcomes for patients with cancer.
- Operate as a life sciences company in the biotechnology sector.
How Does ACUT Make Money?
- Develop and commercialize StemPrintER technology.
- Generate revenue through sales of StemPrintER assays to healthcare providers.
- Establish strategic partnerships with hospitals and cancer centers.
- Pursue regulatory approvals to validate the clinical utility of StemPrintER.
What Industry Does ACUT Operate In?
Accustem Sciences Inc. operates within the biotechnology industry, a sector characterized by rapid innovation and intense competition. The market for cancer diagnostics and personalized medicine is growing, driven by advances in genomics and the increasing demand for targeted therapies. Companies like Accustem are positioned to capitalize on these trends by developing and commercializing novel diagnostic tools. The competitive landscape includes established diagnostic companies and emerging biotechnology firms, all vying for market share. Accustem's success depends on its ability to demonstrate the clinical utility and cost-effectiveness of its StemPrintER technology.
Who Are ACUT's Key Customers?
- Hospitals and cancer centers.
- Oncologists and other healthcare providers.
- Patients with Endocrine receptor-positive /HER2- breast cancer.
Financial Health
Accustem Sciences Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.30 places it in the distress zone, a signal of elevated financial risk.
Accustem Sciences Inc. (ACUT) Valuation Context
Valued at $3.62M, ACUT is classified as a micro-cap stock. Relative to its peer group, ACUT's quantitative score of 42/100 is below the peer average of 64/100.
Company Profile
Accustem Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Wendy E. Blosser. ACUT has traded publicly since 2022.
ACUT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shown increasing optimism, with discussions highlighting recent advancements in their healthcare solutions.
- The company has been gaining attention for its innovative approaches, positioning itself favorably in a growing market.
- Positive developments in partnerships and collaborations have sparked interest, suggesting a strong network that could enhance growth opportunities.
Bear Case
- Concerns about the competitive landscape have emerged, with peers launching similar products that could dilute market share.
- Recent community discussions have included skepticism regarding the scalability of their solutions, raising doubts about long-term sustainability.
- Market perception remains cautious, as some investors are wary of the company's ability to deliver on its growth promises.
- Insider selling activity has raised red flags for some, indicating potential lack of confidence from key stakeholders in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ACUT Latest News
No recent news available for ACUT.
ACUT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACUT.
Price Targets
Wall Street price target analysis for ACUT.
ACUT MoonshotScore
What does this score mean?
The MoonshotScore rates ACUT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Wendy E. Blosser
CEO
Wendy E. Blosser serves as the CEO of Accustem Sciences Inc. Her background includes experience in managing small teams and guiding early-stage companies. Her expertise lies in strategic planning and business development, focusing on driving growth and innovation within the healthcare sector. She is responsible for overseeing the development and commercialization of Accustem's StemPrintER technology. Blosser's leadership is crucial for navigating the competitive biotechnology landscape and securing funding for the company's research and development efforts.
Track Record: Under Wendy E. Blosser's leadership, Accustem Sciences Inc. has focused on advancing its StemPrintER technology and seeking strategic partnerships. Key milestones include the development of Spare, a derivative of StemPrintER, and efforts to secure regulatory approvals. Her tenure has been marked by a focus on personalized medicine and diagnostic tools to improve cancer treatment outcomes. Blosser's strategic decisions aim to position Accustem as a key player in the breast cancer prognosis market.
ACUT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Accustem Sciences Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for less liquidity and transparency. This tier is often populated by companies with limited operating history or those facing financial difficulties.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Greater regulatory scrutiny.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal issues involving the company.
- Development of StemPrintER technology.
- Focus on improving cancer treatment outcomes.
- CEO with experience in strategic planning.
- Company based in New York City.
Accustem Sciences Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for ACUT?
ACUT holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Accustem Sciences Inc. is a life sciences company focused on improving cancer patient outcomes through its StemPrintER technology, a multi-gene prognostic assay. The company operates in …
What does Accustem Sciences Inc. do?
Accustem Sciences Inc. is a biotechnology company focused on developing and commercializing StemPrintER, a multi-gene prognostic assay designed to predict the risk of recurrence in patients with Endocrine receptor-positive/HER2- breast cancer. The company's technology aims to provide personalized medicine solutions by offering clinicians detailed prognostic information to tailor treatment plans. Accustem operates within the competitive healthcare sector, striving to improve cancer treatment outcomes through innovative diagnostic tools.
What do analysts say about ACUT stock?
As of 2026-03-16, formal analyst ratings for Accustem Sciences Inc. (ACUT) are unavailable, likely due to its small market capitalization and OTC listing. Key valuation metrics, such as revenue growth and profitability, are still developing. The company's growth considerations center on the successful commercialization of StemPrintER and potential expansion into new markets. Investors should conduct thorough due diligence and assess the risks associated with early-stage biotechnology companies.
What are the main risks for ACUT?
The main risks for Accustem Sciences Inc. include competition from established diagnostic companies, the potential for technological obsolescence, and regulatory hurdles in securing approvals for its StemPrintER technology. The company's limited financial resources and dependence on a single technology also pose significant risks. Additionally, the OTC market listing introduces liquidity and transparency concerns. Investors should carefully evaluate these risks before considering an investment in ACUT.
How does Accustem Sciences Inc. navigate regulatory approval processes?
Accustem Sciences Inc. is focused on securing regulatory approvals, such as from the FDA, for its StemPrintER technology. The company's regulatory strategy involves conducting clinical trials to demonstrate the efficacy and safety of StemPrintER, compiling comprehensive data packages for submission to regulatory agencies, and engaging with regulatory authorities to address any concerns. Successful navigation of these processes is crucial for gaining market acceptance and reimbursement for StemPrintER.
What is Accustem Sciences Inc.'s drug pipeline status?
Accustem Sciences Inc. does not have a traditional drug pipeline. Instead, the company focuses on developing and commercializing StemPrintER, a diagnostic assay for predicting breast cancer recurrence. The company's pipeline consists of enhancements and expansions to the StemPrintER technology, including the development of Spare, a derivative of StemPrintER. Accustem's key therapeutic area is breast cancer prognosis, and upcoming catalysts include clinical trial results and potential regulatory approvals for StemPrintER.
What are the key factors to evaluate for ACUT?
Accustem Sciences Inc. (ACUT) holds an AI score of 42/100 (low). presents a focused investment opportunity within the biotechnology sector, centered on its StemPrintER technology for breast cancer recurrence prediction. Not financial advice.
How frequently does ACUT data refresh on this page?
ACUT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ACUT's recent stock price performance?
Accustem Sciences Inc. (ACUT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary StemPrintER technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may be outdated or incomplete.
- AI analysis pending for ACUT.